NCT06380907

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 250 (estimated)
• Sponsor: Zai Lab (Hong Kong), Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis

Detailed description

This is a randomized, double-blind, vehicle-controlled, dose-ranging, phase 2 study of ZL-1102 in patients with chronic plaque psoriasis. Approximately 250 patients will be randomized at a ratio of 1:1:1:1:1 to 5 treatment arms for 16 weeks of treatment.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	ZL-1102 1% w/w gel BID for 16 weeks	ZL-1102 1% w/w gel BID for 16 weeks
DRUG	ZL-1102 3% w/w gel BID for 16 weeks	ZL-1102 3% w/w gel BID for 16 weeks
DRUG	ZL-1102 3% w/w gel QD for 16 weeks	ZL-1102 3% w/w gel QD for 16 weeks
DRUG	Placebo ZL-1102 0% w/w gel BID for 16 weeks	Vehicle 0% w/w gel BID for 16 weeks
DRUG	Placebo ZL-1102 0% w/w gel QD for 16 weeks	Vehicle 0% w/w gel QD for 16 weeks

Timeline

• Start date: 2024-05-22
• Primary completion: 2026-02-28
• Completion: 2026-03-01
• First posted: 2024-04-24
• Last updated: 2024-11-05

Locations

10 sites across 1 country: Australia